Australian biotech market today 27/5/09
Wednesday, 27 May, 2009
The All Ordinaries are up nearly 1% to 3816.9 after a couple of days of fairly soft trading. The Health indicies are also up 1% in line with the ASX, although from a lower starting point following a slide that started Tuesday last week.
Ramsay Health Care (ASX:RHC) is up 23c to $11.08 following a 2009 financial year update suggesting core EPS growth will likely be 20%, buoyed by the low interest environment, and up from previous estimates of 10-12% growth.
ResMed, on the other hand, slipped 12c, or 2.5%, in the morning trading to $4.72 after another share buy-back, the third in a week.
Other trading was flat or in line with the overall market trend.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
